Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy by Julia K. Tietze, Danice.

Slides:

Advertisements

Similar presentations

Supplementary Figure S1.

Advertisements

Figure 2. Positive selection of J15 TCR transgenic T cells specific for H60. (A) CD4 by CD8 profiles (left) of thymocytes and numbers (right) of each thymic.

Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation by Juliette Mouriès, Gabriel Moron, Géraldine Schlecht,

SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection by.

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice by Robert G. Newman,

Identification of CD3+CD4−CD8− T Cells as Potential Regulatory Cells in an Experimental Murine Model of Graft-Versus-Host Skin Disease (GVHD) Fumi Miyagawa,

Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer by Ou Cao, Eric Dobrzynski,

Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J

by Silke Huber, Reinhard Hoffmann, Femke Muskens, and David Voehringer

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

Volume 15, Issue 2, Pages (February 2007)

by Norman Nausch, Ioanna E

by Daniel L. Barber, Katrin D. Mayer-Barber, Lis R. V

Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists by Christopher T.

Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients by Devi.

Hans-Peter Raué, Carol Beadling, Jennifer Haun, Mark K. Slifka

by Éric Aubin, Réal Lemieux, and Renée Bazin

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy by Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew Flies, Sarah.

Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products by David-Alexandre.

Volume 25, Issue 11, Pages (November 2017)

Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity by Mikael Maksimow, Mari.

by Jamie Honeychurch, Alison L. Tutt, Thomas Valerius, Ingmar A. F. M

IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis

by Bindu Varghese, Adam Widman, James Do, Behnaz Taidi, Debra K

Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Volume 22, Issue 12, Pages (December 2014)

Minor Antigen Distribution Predicts Site-Specific Graft-versus-Tumor Activity of Adoptively Transferred, Minor Antigen-Specific CD8 T Cells Jessica C.

Volume 18, Issue 5, Pages (May 2003)

Ananda W Goldrath, Michael J Bevan Immunity

Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses William H.D. Hallett, Erik Ames, Maite.

Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects Lisbeth A. Welniak, Lynnette Shorts,

Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation Isabel Barao, Maite.

Volume 13, Issue 1, Pages (January 2006)

NKT Cells Inhibit the Onset of Diabetes by Impairing the Development of Pathogenic T Cells Specific for Pancreatic β Cells Lucie Beaudoin, Véronique.

Volume 31, Issue 1, Pages (July 2009)

Volume 19, Issue 3, Pages (March 2011)

by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy

Protective Capacity of Memory CD8+ T Cells Is Dictated by Antigen Exposure History and Nature of the Infection Jeffrey C. Nolz, John T. Harty Immunity

Volume 33, Issue 1, Pages (July 2010)

Volume 43, Issue 2, Pages (August 2015)

Volume 17, Issue 3, Pages (October 2016)

Volume 29, Issue 6, Pages (December 2008)

Volume 20, Issue 13, Pages (September 2017)

Molecular Therapy - Oncolytics

by Derek Hoi-Hang Ho, and Roger Hoi-Fung Wong

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Volume 18, Issue 3, Pages (March 2003)

Volume 32, Issue 1, Pages (January 2010)

Volume 17, Issue 2, Pages (February 2009)

Opposing Effects of TGF-β and IL-15 Cytokines Control the Number of Short-Lived Effector CD8+ T Cells Shomyseh Sanjabi, Munir M. Mosaheb, Richard A.

CTLA-4 Regulates Induction of Anergy In Vivo

T Cells with Low Avidity for a Tissue-Restricted Antigen Routinely Evade Central and Peripheral Tolerance and Cause Autoimmunity Dietmar Zehn, Michael.

Cecile King, Alex Ilic, Kersten Koelsch, Nora Sarvetnick Cell

Volume 8, Issue 2, Pages (August 2003)

Volume 28, Issue 5, Pages (May 2008)

Volume 38, Issue 6, Pages (June 2013)

Volume 17, Issue 5, Pages (May 2009)

Protective Regulatory T Cell Generation in Autoimmune Diabetes by DNA Covaccination with Islet Antigens and a Selective CTLA-4 Ligand Yelena Glinka,

Volume 20, Issue 3, Pages (March 2012)

Volume 25, Issue 4, Pages (April 2017)

Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response Arup Garu, Gopikrishna.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Volume 20, Issue 6, Pages (June 2004)

Immunization with IR or F/T elicits activated OT-I cells of distinct phenotypes. Immunization with IR or F/T elicits activated OT-I cells of distinct phenotypes.

Volume 2, Issue 6, Pages (December 2012)

Presentation transcript:

Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy by Julia K. Tietze, Danice E. C. Wilkins, Gail D. Sckisel, Myriam N. Bouchlaka, Kory L. Alderson, Jonathan M. Weiss, Erik Ames, Kevin W. Bruhn, Noah Craft, Robert H. Wiltrout, Dan L. Longo, Lewis L. Lanier, Bruce R. Blazar, Doug Redelman, and William J. Murphy Blood Volume 119(13):3073-3083 March 29, 2012 ©2012 by American Society of Hematology

Effects of immunotherapy regimens on memory CD8 T cell expansion and function in vivo. Effects of immunotherapy regimens on memory CD8 T cell expansion and function in vivo. (A) Survival after anti-CD40 and IL-2 treatment of subcutaneously implanted 3LL (left), subcutaneously implanted B16 (middle), or intravenously injected Renca (right) tumor models. (B) Total numbers of splenic CD44highCD8+ T cells on day 11 of anti-CD40 and IL-2 (left) and 5 days after IL-2 and IL-12 (right) immunotherapy regimens in naive mice. (C) BrdU incorporation of CD44highCD8+ T cells in response to immunotherapy. Numbers in dot plots represent percentages of CD8+ T cells. (D) Percentage of naive CD8+ T cells in wildtype and thymectomized mice 11 days after anti-CD40 and IL-2 therapy. (E) Percentage of memory CD8+ T cells in WT and thymectomized mice on day 11 of anti-CD40 and IL-2 treatment. (F) Expression of CD122 on CD44high (dashed line) compared with CD44low CD8+ T cells (shaded) from resting C57BL/6 mice. Data are representative of at least 3 independent experiments (*P < .05, **P < .01, ***P < .001). Julia K. Tietze et al. Blood 2012;119:3073-3083 ©2012 by American Society of Hematology

Phenotype of cytokine induced CD8+ T cells in vivo and in vitro. Phenotype of cytokine induced CD8+ T cells in vivo and in vitro. (A) Gating schema and expression of NKG2D and CD25 on CD44highCD8+ T cells. (B) Percentages of CD25 and/or NKG2D expressing CD44highCD8+ populations in the spleen (left) and lymph node (right) on day 12 of anti-CD40 and IL-2 treatment. (C) Percentage of PD-1+ CD8+ T cells 12 days after anti-CD40 and IL-2 treatment in the spleen and lymph node. (D) Histograms depicting expression of NKG2D+ (left), PD-1+ (middle), and CD25+ (right) CD8+ T cells after anti-CD3 and anti-CD28 (solid line) or IL-2 (dashed line) stimulation compared with media alone (shaded). Data are representative of at least independent experiments (*P < .05, **P < .01, ***P < .001). Julia K. Tietze et al. Blood 2012;119:3073-3083 ©2012 by American Society of Hematology

Characterization of functional ability and tumor efficacy of immunotherapy expanded CD8+ T cells. Characterization of functional ability and tumor efficacy of immunotherapy expanded CD8+ T cells. (A) Granzyme B expression in CD44highCD8+ T cells on day 12 of anti-CD40 and IL-2 treatment. (B) Lytic ability of whole splenocytes (left) or sorted CD44high and CD44low CD8+ T cells (right) from anti-CD40 and IL-2 or control treated animals redirected against anti-CD3 labeled P815 targets. (C) NKG2D expression and (D) quantification of CD25 (pos) and (neg) CD8+ T cells from mice bearing orthotopic Renca tumors. (E) Tumor growth after immunotherapy concurrent with blockade of NKG2D in sc NKG2D ligand expressing Renca tumors. Data are representative of at least 3 independent experiments (*P < .05, **P < .01, ***P < .001). Julia K. Tietze et al. Blood 2012;119:3073-3083 ©2012 by American Society of Hematology

Phenotype of OT-I CD8+ T cells after cytokine immunotherapy versus immunization. Phenotype of OT-I CD8+ T cells after cytokine immunotherapy versus immunization. (A) Expression of Vα2 and Vβ5.1/5.2 on peripheral blood CD8+ T cells from WT (left) and OT-I (right) mice. Numbers in the quadrants denote the percentages of CD8+ T cells expressing each marker. (B) Percentage and (C) numbers of CD44high expressing OT-I cells 11 days after anti-CD40 and IL-2 immunotherapy or OVA vaccination. (D) Dot plots depicting BrdU incorporation gated by CD44high expressing population in adoptively transferred OT-I cells after immunotherapy. Percentages of (E) CD25− and (F) PD-1 expression on CD44highOT-I cells from anti-CD40/IL-2 or OVA-vaccinated mice. (G) Percentage (left) and total numbers (right) of NKG2D+CD25− of CD44highOT-I cells on day 12 of anti-CD40 and IL-2 treatment. (H) Frequencies of NKG2D (left), PD-1 (middle), and CD25 (right) on OT-I cells after in vitro anti-CD3 and anti-CD28 (solid line) or IL-2 (dashed line) stimulations compared with media alone (shaded). Data are representative of at least 2 independent experiments (*P < .05, **P < .01, ***P < .001). Julia K. Tietze et al. Blood 2012;119:3073-3083 ©2012 by American Society of Hematology

Functional analysis of OT-I cells after anti-CD40 and IL-2 treatment. Functional analysis of OT-I cells after anti-CD40 and IL-2 treatment. (A) Granzyme B expression by OT-I T cells on day 12 day of anti-CD40 and IL-2 treatment. (B) Lytic ability (presented as percentage specific lysis at a 50:1 E/T ratio) of OT-I and WT mice on day 12 of anti-CD40 and IL-2 treatment. (C) Specific lysis of OVA-expressing EG7 and OVA-negative EL4 tumor lines after anti-CD40 and IL-2. Presented as percentage specific lysis at a 25:1 E/T ratio. (D) Growth of subcutaneous 3LL tumors in control and anti-CD40/IL-2-treated OT-I and WT mice compared. Data are representative of at least 2 independent experiments (*P < .05, **P < .01, ***P < .001). Julia K. Tietze et al. Blood 2012;119:3073-3083 ©2012 by American Society of Hematology

Human CD8 T cells exhibit similar phenotypic characteristics to mice after in vivo and in vitro antigen nonspecific stimulation. Human CD8 T cells exhibit similar phenotypic characteristics to mice after in vivo and in vitro antigen nonspecific stimulation. CD8 (purple) and CD25 (brown) expression in melanoma lesional biopsies after application of (A) vehicle or (B) 5% imiquimod cream daily for 14 days (40× magnification). (C) Dot plots depict gating schema and expression of HLA-DR and CD25 expression on human CD8+ T cells after 3 days of stimulation with PHA/IL-2 (TCR mimicking) or IL-2 alone in vitro. (D) Percentages of (TCR-dependent) CD25+HLA-DR+ (left) or PD-1+ (right) expressing CD45RO+CD8+ human T cells. (E) Percentage (left) and numbers (right) of CD25−HLA-DR+ (TCR-independently activated) human CD45RO+CD8+ T cells. (F) Percentages of CD25+ (left) and CD25− (right) human CD45RO+CD8+ T cells after 14 days of indicated stimulation. Data are representative of at least 2 independent experiments (*P < .05, **P < .01, ***P < .001). Julia K. Tietze et al. Blood 2012;119:3073-3083 ©2012 by American Society of Hematology